公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companionanimal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
公司地址 10 Sylvan Way, Parsippany, NJ, USA, 07054
電話號碼 +1 973 822-7000
傳真號碼 --
公司網頁 https://www.zoetis.com
員工數量 14500
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Kristin C. Peck Director and Chief Executive Officer 美元 1.35M 08/04/2026
Ms. Roxanne Lagano Executive Vice President, General Counsel and Corporate Secretary 美元 700.00K 12/02/2026
Mr. James K. Saccaro Executive Vice President, Chief Financial Officer and Chief Operating Officer -- 06/08/2026
Ms. Julie Fuller Executive Vice President, Global Operations and Chief Human Resources Officer -- 12/02/2026
Ms. Jeannette Ferran Astorga Executive Vice President, Corporate Affairs and Chief Sustainability Officer -- 12/02/2026
Mr. Jamie Brannan Executive Vice President and Chief Commercial Officer 美元 720.00K 12/02/2026
Ms. Rimma Driscoll Executive Vice President and Head of Global Strategy, Commercial and Business Development and Global BioDevices -- 12/02/2026
Mr. Nick Ashton Executive Vice President and President, Global Manufacturing and Supply -- 12/02/2026
Mr. Keith Sarbaugh Executive Vice President, Chief Digital Officer and Chief Technology Officer -- 12/02/2026
Dr. Kevin Esch Executive Vice President and President, Research and Development -- 12/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Gregory Norden Independent Director 08/04/2026
Mr. Michael B. McCallister Chairman of the Board 08/04/2026
Mr. Paul M. Bisaro Independent Director 08/04/2026
Mr. Frank A. D’Amelio Independent Director 08/04/2026
Mr. Sanjay Khosla Independent Director 08/04/2026
Ms. Kristin C. Peck Director and Chief Executive Officer 08/04/2026
Mr. Gavin D.K. Hattersley Independent Director 08/04/2026
Ms. Stephanie Tilenius Director 08/04/2026
Dr. Willie M. Reed, PhD Independent Director 08/04/2026
Ms. Iris Knobloch Director 13/10/2026
Ms. Antoinette R. Leatherberry Independent Director 08/04/2026
Ms. Vanessa Broadhurst Independent Director 08/04/2026
Mr. Mark Stetter Independent Director 08/04/2026
 
所屬ETF (更新日期: 31/10/2026 03:22)
代號 名稱 佔比% ▼ 持有日期
DFACDimensional US Core Equity 2 ETF0.002%30/09/2026
DXUVDimensional US Vector Equity ETF0.002%24/09/2026
ISPYProShares S&P 500 High Income ETF0.001%30/09/2026
DRUPGraniteShares Nasdaq Sel Disruptors ETF0.001%30/09/2026
GGUSGoldman Sachs MktBt Russell LgCpGrEqETF0.001%30/09/2026
AVSUAvantis Responsible US Equity ETF0.001%30/09/2026
GABGabelli Equity Trust0.001%30/06/2026
USNZXtrackers Net Zero Pwy Par Alg US Eq ETF0.001%30/09/2026
TSPAT. Rowe Price US Equity Research ETF0.001%30/09/2026
HAPIHarbor Human Capital Factor US LrgCapETF0.001%30/09/2026
XVViShares ESG Select Screened S&P 500 ETF0.001%30/09/2026
BUYBProShares S&P 500 Buybck Arstcrts ETF0.001%30/09/2026
AAUBAlpha Architect US Equity 4 ETF0.001%30/09/2026
CVMCCalvert US Mid-Cp Cor Rspnb ETF0.001%30/09/2026
PQUSPictet AI Enhanced US Equity ETF0.001%30/09/2026
JUSAJPMorgan U.S. Research Enh Lg Cp ETF0.001%30/09/2026
PRAYFIS Christian Stock ETF0.001%30/09/2026
DVGRDAC 3D Dividend Growth ETF0.001%30/09/2026
EQLALPS Equal Sector Weight ETF0.001%30/09/2026
RXLProShares Ultra Health Care0.001%30/09/2026
  1    2    3    4    5    6    7    8    9   10    11    12    13    14    15    16    17    18    19    20  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.